Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Scand J Surg ; 107(1): 14-22, 2018 Mar.
Article in English | MEDLINE | ID: mdl-28401771

ABSTRACT

BACKGROUND AND AIMS: Preoperative magnetic resonance imaging has become an important complementary imaging technique in patients with breast cancer, providing additional information for preoperative local staging. Magnetic resonance imaging is recommended selectively in lobular breast cancer and in patients with dense breast tissue in the case when mammography and ultrasound fail to fully evaluate the lesion, but the routine use of magnetic resonance imaging in all patients with invasive ductal carcinoma is controversial. The purpose of this randomized study was to investigate the diagnostic value of preoperative magnetic resonance imaging and its impact on short-term surgical outcome in newly diagnosed unifocal stage I invasive ductal carcinoma. MATERIAL AND METHODS: A total of 100 patients were randomized to either receive preoperative breast magnetic resonance imaging or to be scheduled directly to operation without magnetic resonance imaging on a 1:1 basis. There were 50 patients in both study arms. RESULTS: In 14 patients (28%), breast magnetic resonance imaging detected an additional finding and seven of them were found to be malignant. Six additional cancer foci were found in the ipsilateral breast and one in the contralateral breast. Magnetic resonance imaging findings caused a change in planned surgical management in 10 patients (20%). Mastectomy was performed in six patients (12%) in the magnetic resonance imaging group and in two patients (4%) in the control group ( p = 0.140). The breast reoperation rate was 14% in the magnetic resonance imaging group and 24% in the control group ( p = 0.202). The mean interval between referral and first surgical procedure was 34 days in the magnetic resonance imaging group and 21 days in the control group ( p < 0.001). CONCLUSION: Preoperative magnetic resonance imaging may be beneficial for some patients with early-stage invasive ductal carcinoma, but its routine use is not recommended without specific indications.


Subject(s)
Breast Neoplasms/diagnostic imaging , Breast Neoplasms/surgery , Carcinoma, Ductal, Breast/diagnostic imaging , Carcinoma, Ductal, Breast/surgery , Magnetic Resonance Imaging/methods , Neoplasm Recurrence, Local/epidemiology , Aged , Aged, 80 and over , Biopsy, Needle , Breast Neoplasms/mortality , Carcinoma, Ductal, Breast/mortality , Disease-Free Survival , Female , Finland , Hospitals, University , Humans , Immunohistochemistry , Mastectomy, Segmental/methods , Middle Aged , Neoplasm Recurrence, Local/pathology , Neoplasm Recurrence, Local/surgery , Preoperative Care/methods , Prognosis , Prospective Studies , Risk Assessment , Statistics, Nonparametric , Survival Analysis , Treatment Outcome
3.
Refuat Hapeh Vehashinayim (1993) ; 32(3): 44-51, 70, 2015 Jul.
Article in Hebrew | MEDLINE | ID: mdl-26548150

ABSTRACT

Endoscopic surgery has changed the philosophy and practice of modern surgery in all aspects of medicine. It gave rise to minimally invasive surgery procedures based on the ability to visualize and to operate via small channels. In maxillofacial surgery, our ability to see clearly the surgical field opened an entirely new world of exploration, as conditions that were once almost impossible to control and whose outcome was uncertain can be now predictably managed. in this article we will descripe the advantage of using the oral endoscope during the dental implantology procedure, and we will describe a unique implant which enable us in combination with the oral endoscope to create a maxillary sinus lift with out the need of the major surgery with all of its risks and complication.


Subject(s)
Dental Implantation/methods , Endoscopy/methods , Minimally Invasive Surgical Procedures/methods , Oral Surgical Procedures/methods , Endoscopes , Humans , Maxillary Sinus/surgery
4.
Leukemia ; 26(8): 1850-61, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22354283

ABSTRACT

All-trans retinoic acid (ATRA) is the only clinically useful differentiating agent, being used in the treatment of acute promyelocytic leukemia (APL). The use of ATRA in other types of acute myelogenous leukemia (AML) calls for the identification of novel strategies aimed at increasing its therapeutic activity. Here, we provide evidence that pharmacological inhibition of the mitogen-activated protein kinase, p38α, or silencing of the corresponding gene sensitizes APL and AML cell lines, as well as primary cultures of AML blasts to the anti-proliferative and cyto-differentiating activity of ATRA and synthetic retinoids. P38α inhibits ligand-dependent transactivation of the nuclear retinoic acid receptor, RARα, and the derived chimeric protein expressed in the majority of APL cases, PML-RARα. Inhibition is the consequence of ligand-independent binding of p38α, which results in stabilization of RARα and PML-RARα via blockade of their constitutive degradation by the proteasome. The inhibitory effect requires a catalytically active p38α and direct physical interaction with RARα and PML-RARα. Ser-369 in the E-region of RARα is essential for the binding of p38α and the ensuing functional effects on the activity of the receptor.


Subject(s)
Antineoplastic Agents/pharmacology , Leukemia, Myeloid, Acute/metabolism , Mitogen-Activated Protein Kinase 14/metabolism , Receptors, Retinoic Acid/metabolism , Retinoids/pharmacology , Animals , Antineoplastic Agents/therapeutic use , Cell Differentiation/drug effects , Cell Line , Cell Proliferation/drug effects , Chlorocebus aethiops , Gene Expression Regulation, Leukemic , Gene Silencing , Humans , Leukemia, Myeloid, Acute/drug therapy , Leukemia, Myeloid, Acute/genetics , Ligands , Mice , Mitogen-Activated Protein Kinase 14/antagonists & inhibitors , Mitogen-Activated Protein Kinase 14/genetics , Oncogene Proteins, Fusion/genetics , Protein Binding , Protein Stability , Receptors, Retinoic Acid/genetics , Retinoic Acid Receptor alpha , Retinoids/therapeutic use , Transcription, Genetic
5.
J R Soc Interface ; 9(69): 677-88, 2012 Apr 07.
Article in English | MEDLINE | ID: mdl-21957117

ABSTRACT

Haemodynamics and morphology play an important role in the genesis, growth and rupture of cerebral aneurysms. The goal of this study was to generate and analyse statistical wall shear stress (WSS) distributions and shapes in middle cerebral artery (MCA) saccular aneurysms. Unsteady flow was simulated in seven ruptured and 15 unruptured MCA aneurysms. In order to compare these results, all geometries must be brought in a uniform coordinate system. For this, aneurysms with corresponding WSS data were transformed into a uniform spherical shape; then, all geometries were uniformly aligned in three-dimensional space. Subsequently, we compared statistical WSS maps and surfaces of ruptured and unruptured aneurysms. No significant (p > 0.05) differences exist between ruptured and unruptured aneurysms regarding radius and mean WSS. In unruptured aneurysms, statistical WSS map relates regions with high (greater than 3 Pa) WSS to the neck region. In ruptured aneurysms, additional areas with high WSS contiguous to regions of low (less than 1 Pa) WSS are found in the dome region. In ruptured aneurysms, we found significantly lower WSS. The averaged aneurysm surface of unruptured aneurysms is round shaped, whereas the averaged surface of ruptured cases is multi-lobular. Our results confirm the hypothesis of low WSS and irregular shape as the essential rupture risk parameters.


Subject(s)
Intracranial Aneurysm/physiopathology , Adult , Aged , Cerebrovascular Circulation , Computer Simulation , Female , Hemodynamics , Humans , Intracranial Aneurysm/pathology , Male , Middle Aged , Models, Cardiovascular , Risk Factors , Rupture, Spontaneous/pathology , Rupture, Spontaneous/physiopathology , Shear Strength
6.
Rheumatol Int ; 32(9): 2629-36, 2012 Sep.
Article in English | MEDLINE | ID: mdl-21833523

ABSTRACT

Cryopyrinopathies are a subgroup of autoinflammatory syndromes. Most cases have mutations in the CIAS1/NLRL3 gene, encoding the cryopyrin/NLRP3 protein. Cryopyrin, together with other proteins, is involved in the assembly of the cryopyrin/NLRP3 inflammasome. Mutations in CIAS1/NLRP3 result in increased IL-1ß cleavage from biologically inactive pro-IL-1ß. This results in systemic inflammation and three associated disorders of different severity, forming a clinical continuum with overlapping features. The mildest from, familial cold autoinflammatory syndrome (FCAS), is characterized by remitting fevers, urticaria-like rash, polyarthralgia/arthritis, and usually caused by cold exposure. More severe forms are Muckle-Wells syndrome (MWS) and CINCA/NOMID. We report an 8-year-old boy with FCAS, who presented with overlapping features with MWS. He showed good response to seasonal anakinra treatment. Mutation analysis in CIAS1/NLRP3, PYCARD, and CASP1 was performed. Serum cytokine profiles, and cytokine expression from resting monocytes, and in response to mild hypothermia, and LPS stimulation were determined. Mutations in CIAS1/NLRP3, PYCARD, and CASP1 were not found. In response to mild hypothermia, an enhanced IL-1ß expression by patient monocytes resulted in increased IL-6 and TNF-α secretion, as compared to control cells. The addition of the IL-1ß receptor antagonist (anakinra) reversed these effects. In response to LPS stimulation, patient monocytes produced high level of IL-1ß, IL-6 and TNF-α. This was markedly less pronounced in control monocytes. FCAS results in cold-induced cytokine dysregulation and systemic inflammation. Symptoms can be treated, using IL-1ß antagonists. Further research is warranted, particularly in order to investigate pathophysiological mechanisms in "mutation negative" individuals.


Subject(s)
Carrier Proteins/genetics , Caspase 1/genetics , Cryopyrin-Associated Periodic Syndromes/genetics , Cryopyrin-Associated Periodic Syndromes/physiopathology , Cytoskeletal Proteins/genetics , Mutation/genetics , Antirheumatic Agents/therapeutic use , CARD Signaling Adaptor Proteins , Child , Cryopyrin-Associated Periodic Syndromes/drug therapy , Cytokines/metabolism , DNA Mutational Analysis , Humans , Interleukin 1 Receptor Antagonist Protein/therapeutic use , Male , Monocytes/metabolism , NLR Family, Pyrin Domain-Containing 3 Protein , Treatment Outcome
7.
Rheumatol Int ; 32(11): 3525-30, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22083619

ABSTRACT

Systemic onset juvenile idiopathic arthritis (SoJIA) is a rare inflammatory disorder. It can result in disease and treatment-related disability. SoJIA is characterized by remitting fevers, evanescent rash, generalized lymphadenopathy, hepatomegaly/splenomegaly, and/or serositis. Non-responsiveness to standard therapy with corticosteroids and disease modifying antirheumatic drugs is not uncommon. IL-1ß has been shown to be a main contributor to the pathogenesis of SoJIA. Anakinra, a recombinant IL-1ß receptor antagonist, was shown to be effective in small cohorts of therapy-resistant adult and pediatric Still's patients. In order to assess the efficacy and safety of first-line anakinra treatment in SoJIA, we reviewed the charts of all SoJIA patients in our institution from 2005 to 2010, searching for first-line anakinra-treated patients. We report the clinical and laboratory course of four SoJIA patients. The mean follow-up was 13.5 (range: 2-50) months. Anakinra was started at doses from 1.5 to 4 mg/kg for a median duration of 3 (range: 3-18) months. Two patients responded to anakinra mono-therapy; two cases required corticosteroids. Normalized body temperatures and the absence of evanescent rashes were achieved after a median of 4 (range: 2-10) days. We did not see treatment-related adverse reactions other than local injection site inflammation. This is the first single-center series, reporting anakinra as first-line treatment in SoJIA. We show rapid efficacy of anakinra in early SoJIA with reduced treatment-related side effects. A subset of patients remains corticosteroid dependent. Further studies are warranted to follow larger cohorts and to assess long-term safety.


Subject(s)
Antirheumatic Agents/therapeutic use , Arthritis, Juvenile/drug therapy , Interleukin 1 Receptor Antagonist Protein/therapeutic use , Antirheumatic Agents/adverse effects , Arthritis, Juvenile/blood , Child , Child, Preschool , Cytokines/blood , Female , Humans , Interleukin 1 Receptor Antagonist Protein/adverse effects , Male , Treatment Outcome
8.
Mol Cell Biol ; 31(7): 1409-18, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21262770

ABSTRACT

The induction of the granulocytic differentiation of leukemic cells by all-trans retinoic acid (RA) has been a major breakthrough in terms of survival for acute promyelocytic leukemia (APL) patients. Here we highlight the synergism and the underlying novel mechanism between RA and the granulocyte colony-stimulating factor (G-CSF) to restore differentiation of RA-refractory APL blasts. First, we show that in RA-refractory APL cells (UF-1 cell line), PML-RA receptor alpha (RARα) is not released from target promoters in response to RA, resulting in the maintenance of chromatin repression. Consequently, RARα cannot be recruited, and the RA target genes are not activated. We then deciphered how the combination of G-CSF and RA successfully restored the activation of RA target genes to levels achieved in RA-sensitive APL cells. We demonstrate that G-CSF restores RARα recruitment to target gene promoters through the activation of the extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) pathway and the subsequent derepression of chromatin. Thus, combinatorial activation of cytokines and RARs potentiates transcriptional activity through epigenetic modifications induced by specific signaling pathways.


Subject(s)
Cell Differentiation/drug effects , Extracellular Signal-Regulated MAP Kinases/biosynthesis , Granulocyte Colony-Stimulating Factor/pharmacology , Histones/metabolism , Leukemia, Promyelocytic, Acute/pathology , Promoter Regions, Genetic/genetics , Receptors, Retinoic Acid/metabolism , Cell Differentiation/genetics , Cell Line, Tumor , Chromatin Assembly and Disassembly/drug effects , Enzyme Activation/drug effects , Enzyme Induction/drug effects , Gene Expression Regulation, Leukemic/drug effects , Humans , Leukemia, Promyelocytic, Acute/enzymology , Leukemia, Promyelocytic, Acute/genetics , MAP Kinase Signaling System/drug effects , Mitogen-Activated Protein Kinase 3/biosynthesis , Mitogen-Activated Protein Kinase 6/biosynthesis , Phosphorylation/drug effects , Protein Binding/drug effects , Protein Processing, Post-Translational/drug effects , Retinoic Acid Receptor alpha , Transcription, Genetic/drug effects , Tretinoin/pharmacology
9.
Scand J Rheumatol ; 37(5): 385-9, 2008.
Article in English | MEDLINE | ID: mdl-18609262

ABSTRACT

Chronic infantile neurological cutaneous and articular (CINCA) syndrome is an autoinflammatory disease, defined by the triad of urticarial rash, neurological manifestations, and arthropathy, accompanied by recurrent fevers and systemic inflammation. Increasing neurological deficits result from aseptic meningitis. Sensorineural hearing loss and progressive loss of vision caused by keratoconjunctivitis or papilloedema may emerge. An autosomal-dominant inheritance is suspected although sporadic cases are reported frequently. Sixty per cent of CINCA patients carry mutations in the cold-induced autoinflammatory syndrome (CIAS1) gene. We report the favourable response of a 23-year-old CINCA patient without CIAS1 mutations to treatment with the recombinant interleukin-1 (IL-1) receptor antagonist anakinra.


Subject(s)
Carrier Proteins/genetics , Interleukin 1 Receptor Antagonist Protein/therapeutic use , Interleukin-1beta/antagonists & inhibitors , Mutation/genetics , Nervous System Diseases/drug therapy , Rheumatic Diseases/drug therapy , Urticaria/drug therapy , Adult , Antirheumatic Agents/therapeutic use , Female , Humans , NLR Family, Pyrin Domain-Containing 3 Protein , Nervous System Diseases/genetics , Rheumatic Diseases/genetics , Syndrome , Urticaria/genetics
10.
Z Rheumatol ; 67(2): 145-8, 150, 2008 Mar.
Article in German | MEDLINE | ID: mdl-18309500

ABSTRACT

Osteoid osteomas are painful bone tumors that usually occur in childhood or adolescence. Despite the small size of the bony lesions osteoid osteomas can cause persistent pain. Pathogenesis has not been completely understood. Remission usually occurs within several months to years. Therefore surgical therapy is not indicated in all cases. Nevertheless, as a result of reduced quality of life due to pain, sufficient analgesic/antiinflammatory therapy needs to be provided. We report on two male patients, aged 10 and 14 years, who presented with arthritis of the finger joints. As a result of both patients' histories, and following radiographic imaging and magnetic resonance imaging, a diagnosis of osteoid osteoma was made. Remission could be achieved in both patients following treatment with nonsteroidal antiinflammatory drugs (NSAIDs).In addition to the typical sites at the long bones of the lower extremity, osteoid osteomas can also localize to other sites such as fingers. In the case of definitive diagnosis and under close follow-up, medical treatment with NSAIDs is an alternative to surgical strategies. The operative risk should be weighed against the risk of long-term treatment with NSAIDs.


Subject(s)
Bone Neoplasms/diagnosis , Finger Phalanges/pathology , Osteoma, Osteoid/diagnosis , Adolescent , Child , Humans , Male , Rare Diseases/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...